Annexin Pharmaceuticals AB (OSTO:ANNX) Tax Provision: kr0.00 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:ANNX Annexin Pharmaceuticals AB OSTO:ANNX
23 GF Score
Price kr12.50
! 1 Warning Sign
View Full Analysis

What is Annexin Pharmaceuticals AB Tax Provision?

Annexin Pharmaceuticals AB OSTO:ANNX -1.60% 23 Tax Provision is kr0.00 Mil as of Mar. 2026. GuruFocus rates OSTO:ANNX with a GF Score™ of 23/100. The stock has 1 warning sign investors should review.

Annexin Pharmaceuticals AB's tax provision for the three months ended in Mar. 2026 was kr0.00 Mil. Its tax provision for the trailing twelve months (TTM) ended in Mar. 2026 was kr0.00 Mil.

Annexin Pharmaceuticals AB Tax Provision Historical Data

* Premium members only.

The historical data trend for Annexin Pharmaceuticals AB's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Annexin Pharmaceuticals AB Tax Provision Chart

Annexin Pharmaceuticals AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Tax Provision
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Annexin Pharmaceuticals AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Tax Provision Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
OSTO:ANNX
23GF Score
Annexin Pharmaceuticals AB OSTO:ANNX
Tax Provision is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Annexin Pharmaceuticals AB Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Tax Provision →
What does a Tax Provision of kr0.00 Mil mean?
Annexin Pharmaceuticals AB (OSTO:ANNX) has a Tax Provision of kr0.00 Mil as of Mar. 2026. Provision for taxes is the amount of tax the company owes based on pre-tax income. View historical data on Annexin Pharmaceuticals AB and its competitors.
Is Annexin Pharmaceuticals AB's Tax Provision too high?
Annexin Pharmaceuticals AB's current Tax Provision is kr0.00 Mil. Overall, Annexin Pharmaceuticals AB has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Annexin Pharmaceuticals AB's Tax Provision compare to VRTX and REGN?
Annexin Pharmaceuticals AB's Tax Provision of kr0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tax Provision for a Biotechnology company?
A good Tax Provision depends on the Biotechnology industry context. However, Tax Provision should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tax Provision mean?
A high Tax Provision can signal that a stock is expensive relative to its fundamentals. Provision for taxes is the amount of tax the company owes based on pre-tax income. View historical data on Annexin Pharmaceuticals AB and its competitors. Annexin Pharmaceuticals AB's current Tax Provision is kr0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Annexin Pharmaceuticals AB stock overvalued right now?
Annexin Pharmaceuticals AB (OSTO:ANNX) has a current Tax Provision of kr0.00 Mil. The current Tax Provision is kr0.00 Mil. Annexin Pharmaceuticals AB's overall GF Score™ is 23/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tax Provision calculated?
Tax Provision is calculated from a company's financial statements. For Annexin Pharmaceuticals AB (OSTO:ANNX), the current Tax Provision is kr0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Annexin Pharmaceuticals AB Business Description

Other Exchanges Q910:Germany
Address Kammakargatan 48, Stockholm, SWE, 111 60
Annexin Pharmaceuticals AB is a biotechnology company. It is developing biological drug candidate ANXV, a recombinant human protein Annexin A5 for treatment of various cardiovascular diseases. The company also focuses on development of ANXV for the treatment of retinal vein occlusion.
23GF Score

Get the complete analysis for OSTO:ANNX

Tax Provision is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr12.50
Price